10-Q: Orthofix Medical Reports Q2 2026 Results, Revenue Up, Net Loss Continues

Orthofix Medical Inc. announced its second quarter 2026 financial results, showing a 3.8% increase in net sales to $210.9 million, but a net loss of $15.8 million.

Summary

• Orthofix Medical Inc. reported net sales of $210.9 million for the three months ended June 30, 2026, an increase of 3.8% compared to $203.1 million in the prior year period.
• The company reported a net loss of $15.8 million for the quarter, compared to a net loss of $14.1 million in the same period last year.
• For the six months ended June 30, 2026, net sales were $407.6 million, an increase of 2.7% compared to $396.8 million in the prior year period.
• The net loss for the six-month period was $36.7 million, compared to $67.2 million in the prior year period.
• Gross profit for the quarter increased by 7.3% to $149.7 million, with gross margin improving to 71.0% from 68.7% in the prior year.
• Sales, general, and administrative expenses increased slightly to $138.0 million from $136.5 million.
• Research and development expenses remained stable at $15.9 million.
• Cash and cash equivalents increased to $103.8 million as of June 30, 2026, from $82.0 million as of December 31, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the continued net loss, increased interest expense, and a decrease in free cash flow, despite revenue growth and improved gross margins.

Positives

• Net sales increased by 3.8% to $210.9 million for the three months ended June 30, 2026.
• Global Limb Reconstruction segment showed strong growth with net sales increasing by 13.2% to $37.7 million.
• Gross profit increased by 7.3% to $149.7 million, and gross margin improved to 71.0% from 68.7%.
• Therapeutic Solutions net sales increased by 2.5% to $64.2 million.
• Spinal Implants, Biologics, and Enabling Technologies net sales increased by 4.0% to $109.0 million (excluding M6 product lines).
• Cash and cash equivalents increased to $103.8 million from $82.0 million.
• The company was in compliance with all required financial covenants under its credit agreement.

Negatives

• The company reported a net loss of $15.8 million for the three months ended June 30, 2026, an increase from $14.1 million in the prior year.
• Interest expense, net, increased significantly by 54.1% to $6.1 million due to increased borrowings.
• Free cash flow for the six months ended June 30, 2026, was negative $47.1 million, a decrease from negative $20.6 million in the prior year.
• Accounts receivable increased slightly to $135.8 million, and inventory increased to $184.5 million.
• The Lattus Contingent Consideration obligation remains at $9.5 million as of June 30, 2026, with a $5.1 million payment made on July 1, 2026.
• The company recorded $1.1 million for attorneys' fees, costs, and expenses related to the Keith Valentine arbitration award.

Risks

• The FDA's reclassification of bone growth stimulator devices from Class III to Class II may increase competition and adversely affect future sales.
• Increased competition could lead to pricing pressure and reduced demand or market share.
• The company faces ongoing legal proceedings, including securities class action complaints and derivative shareholder complaints, with an inability to reasonably estimate potential losses.
• The Italian Medical Device Payback (IMDP) liability is accrued at $11.0 million, with the potential for the actual liability to be higher or lower.
• The company assumed a contingent consideration obligation related to the Lattus Contingent Consideration, which could result in payments higher or lower than the estimated fair value.
• The company is in negotiations with a distributor regarding a buyout option, the consummation of which may be deferred.

Future Outlook

The company's outlook is influenced by continued investment in direct sales channels, stabilization in Biologics, and the impact of the FDA's reclassification of bone growth stimulators. Management expects reimbursement for bone growth stimulators to return to pre-May 18, 2026 rates following CMS guidance.

Management Comments

• Second quarter 2026 reported net sales of $210.9 million, representing an increase of 4% on a reported basis and 5% on a pro forma constant currency basis compared to second quarter 2025.
• Generated double-digit constant currency growth in Global Spine Fixation and Global Limb Reconstruction, reflecting strong international performance and continued demand across key growth platforms.
• Therapeutic Solutions delivered 3% year-over-year net sales growth despite a temporary Medicare reimbursement headwind affecting bone growth stimulators during part of the second quarter.
• Biologics stabilized and began to regain momentum, supported by focused commercial execution.
• Second quarter 2026 reported net loss of $(15.8) million and non-GAAP adjusted EBITDA of $20.1 million.

Industry Context

StockSavvy.ai notes that Orthofix Medical operates in the competitive medical technology sector, focusing on spinal implants and limb reconstruction. The company's performance is influenced by regulatory changes (like the FDA's reclassification of bone growth stimulators), reimbursement policies (CMS), and the adoption of new technologies by surgeons. The reported revenue growth, particularly in Global Limb Reconstruction, suggests some success in expanding market share, but the persistent net loss and increased debt servicing costs highlight ongoing financial challenges.

Comparison to Industry Standards

• The reported net sales growth of 3.8% for the quarter is moderate within the medical device industry, where growth rates can vary significantly by sub-sector.
• The improvement in gross margin to 71.0% is a positive sign, indicating better cost management or pricing power, which is generally in line with or better than many established medical device companies.
• The continued net loss and negative free cash flow are areas of concern. Many mature medical device companies in the spine and orthopedics space are profitable and generate positive cash flow, though growth-stage companies may still be investing heavily.
• Competitors in the spine market include large players like Medtronic, Johnson & Johnson (DePuy Synthes), and Stryker, as well as specialized companies. In limb reconstruction, competitors include Zimmer Biomet and Smith+Nephew.
• The company's reliance on distributors and sales representatives is a common model in the industry, but it can lead to higher sales and marketing expenses, as seen in the SG&A figures.

Legal Proceedings

• Arbitration claims with former executives Keith Valentine, John Bostjancic, and Patrick Keran resulted in an interim award of $11.8 million plus interest to Mr. Valentine, with a total payment of $14.8 million made by the company. Mr. Keran and Mr. Bostjancic settled for $4.25 million each.
• A securities class action complaint (Bernal v. Orthofix Medical Inc.) alleges materially false and misleading statements between October 11, 2022, and September 12, 2023.
• A consolidated securities class action (In re Orthofix Medical Inc. Securities Litigation) alleges violations of the Securities Act and Exchange Act related to the merger with SeaSpine.
• Derivative shareholder complaints have been filed against current and former officers and directors alleging derivative liability for claims made in the securities complaints.
• The company is defending against claims filed by former executives against former director Catherine Burzik and current director Wayne Burris for defamation, false light invasion of privacy, and other torts.

Related Party Transactions

• The company assumed a contingent consideration obligation under a purchase agreement between SeaSpine and Lattus Spine LLC, requiring potential installment payments based on future net sales of certain products.

Stakeholder Impact

• Shareholders: Continued net losses and negative free cash flow may impact shareholder value and confidence. Legal proceedings introduce uncertainty.
• Creditors: Increased interest expense due to higher debt levels may impact the company's ability to service its debt, although current covenants are met.
• Suppliers: No specific impact mentioned, but general business operations continue.
• Customers: The FDA reclassification of bone growth stimulators could lead to increased competition, potentially affecting product availability or pricing for customers.
• Employees: Continued investment in commercial and support functions suggests ongoing employment opportunities, but financial performance can influence future staffing decisions.

Next Steps

• Continue to invest in direct sales channels for Therapeutic Solutions.
• Focus on commercial execution for Biologics to regain momentum.
• Monitor the impact of the FDA's reclassification of bone growth stimulators on competition and sales.
• Resolve negotiations with the distributor regarding the buyout option.
• Continue to manage legal proceedings and potential liabilities.

Key Dates

Recommendation

While revenue growth and improved gross margins are positive, the continued net loss, increased interest expense, and deteriorating free cash flow present significant concerns. The ongoing legal proceedings add substantial uncertainty. The company's ability to achieve profitability and positive cash flow in the near term is questionable, warranting a cautious 'hold' stance until these issues are resolved and a clear path to profitability emerges.

Keywords

Orthofix Medical, Medical Technology, Spine Implants, Limb Reconstruction, Therapeutic Solutions, Biologics, Financial Results, Quarterly Report